Novartis has boosted its 2024 outlook for a second time this year, thanks to strong sales for some of its biggest drugs used to treat heart failure and other ailments.
Novartis lifts guidance again as demand climbs for top drugs
Read Next
- FBI searches homes of Indiana University professor
- Newsmax stock starts trading on NYSE
- AMC bets on premium screens as Hollywood slate boasts blockbusters
- United Microelectronics shares pop on GlobalFoundries deal report
- XTB’s Head of Risk Management Andrzej Przybylsk to step down
- Takes on rivals OpenAI, Anthropic
- DTCC adds Cenk Kamis of Citi and Laide Majiyagbe of BNY to its Board of Directors
